Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2024 11:00 ET | Source: Nykode Therapeutics ASA

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe

OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
August 14, 2024 01:00 ET | Source: Nykode Therapeutics ASA

Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines

OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
June 20, 2024 01:00 ET | Source: Nykode Therapeutics ASA

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting

OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
June 11, 2024 01:00 ET | Source: Nykode Therapeutics ASA

Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy

OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
May 14, 2024 01:15 ET | Source: Nykode Therapeutics ASA

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer

OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
May 14, 2024 01:00 ET | Source: Nykode Therapeutics ASA

Nykode Therapeutics - Quarterly report Q1 2024

OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
April 19, 2024 01:00 ET | Source: Nykode Therapeutics ASA

Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
March 21, 2024 02:00 ET | Source: Nykode Therapeutics ASA

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Updated survival data from Phase 2 trial (C-02) in advanced cervical cancer affirm prolonged benefits and indicate a synergistic treatment effect of Nykode’s VB10.16 and atezolizumab (Tecentriq®).New...
March 19, 2024 02:00 ET | Source: Nykode Therapeutics ASA

Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases

OSLO, Norway, March 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
November 15, 2023 04:30 ET | Source: Nykode Therapeutics ASA

Nykode Therapeutics - Quarterly report Q3 2023

OSLO, Norway, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...